ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Specialty Generics Firm Goes To Pfizer

by Michael McCoy
July 21, 2014 | APPEARED IN VOLUME 92, ISSUE 29

Pfizer has agreed to acquire InnoPharma, a Piscataway, N.J.-based supplier of hard-to-manufacture injectable generic drugs. Pfizer will pay InnoPharma’s owners $225 million, plus up to $135 million in milestone payments. Pfizer says InnoPharma’s portfolio—10 injectable generics approved by FDA and 19 filed with the agency—will bring its own product line up to 73 approved and filed generic injectables.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment